lifestyle.xbode.org

Author: China Medical System Holdings Ltd.

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

April 23, 2026
CMS(867.HK/8A8.SG): New Drug for Renal Anaemia Desidustat Tablets Approved in China

March 13, 2026
CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

March 13, 2026
CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity

March 5, 2026
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

February 24, 2026
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

January 30, 2026